PRELIMINARY PROGRAM. MELANOMA BRIDGE 2015 Hotel Excelsior, Naples, Italy Sala Partenope December 1-4, 2015

Transcription

1 PRELIMINARY PROGRAM MELANOMA BRIDGE 2015 Hotel Excelsior, Naples, Italy Sala Partenope December 1-4, 2015 December 1 st Opening Ceremony 5:00 PM Opening Ceremony with "patients meet the experts" Session December 2 nd Molecular and Immuno advances Chairpersons: Gerardo Botti, Ena Wang 9:30 AM Michael Davies Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma 9:55 AM Michael Krauthammer Insights from Sequencing the Melanoma Exome 10:20 AM Roger Lo Genomic, epigenomic and immune evolution of melanoma acquiring resistance to MAPK-targeted therapies 10:45 AM Gennaro Ciliberto Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance 11:10 AM Break 11:25 AM Stefani Spranger Tumor-intrinsic beta-catenin signaling mediates tumorimmune avoidance 11:50 AM Cassian Yee Endogenous T Cell Therapy: The next generation 12:15 PM Dung Le* 12:40 PM Discussion 1:25 PM Lunch Combination Therapies Chairpersons: Paolo A. Ascierto, Claus Garbe 2:25 PM Sandra Demaria Harnessing radiotherapy to improve responses to immunotherapy in cancer 2:50 PM Samir Khleif New Strategies in Combination Immune Therapy 3:15 PM Yang Xin Fu Targeting tumor tissue to increase innate sensing for immunotherapy 3:40 PM Reinhard Dummer Biomarkers for treatment decision? 4:05 PM Break 4:20 PM Igor Puzanov Combining oncolytic therapies in the era of checkpoint inhibitors 4:45 PM Steve O'Day Combination therapy in melanoma-for whom?

2 5:10 PM Michael Postow Immune checkpoint blockade for melanoma: Should we combine or sequence ipilimumab and PD-1 antibody therapy? 5:35 PM Nicola Mozzillo Surgery as a therapeutic option in metastatic stage IV melanoma 6:00 PM Roundtable 6:45 PM Conclusions December 3 rd News on Immunotherapy Chairpersons: Michele Maio, Giuseppe Palmieri 9:00 AM Ahmad Tarhini An update on adjuvant and neoadjuvant 9:25 AM Sanjiv Agarwala Overview of intralesional oncolytic therapy 9:50 AM Alexander Eggermont Update on adjuvant ipilimumab EORTC18071, update on ongoing adjuvant pembrolizumab EORTC1325 trials 10:15 AM Sponsored Symposium* 11:15 AM Break 11:30 AM Hassane Zarour Targeting multiple inhibitory pathways in melanoma 11:55 AM Howard Kaufman* 12:20 PM David Stroncek Improving Adoptive Immune Therapy using Genetically Engineered T cells 12:45 PM Discussion 1:30 PM Lunch Tumor Microenvironment and Biomarkers Chairpersons: Giuseppe Masucci, Alessandro Testori 2:30 PM Soldano Ferrone Grp94 and BRAF inhibitor resistance 2:55 PM Thomas Gajewski Tumor and host factors mediating resistance to immunotherapy 3:20 PM Janis M. Taube Multiparameter pathologic assessment of the PD-1/PD-L1 pathway in melanoma 3:45 PM Jennifer A. Wargo 4:10 PM Break 4:25 PM Bernard A. Fox Developing Cancer Immunotherapy Strategies that Change the Tumor Microenvironment and Eliminate Cancer 4:50 PM Licia Rivoltini Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? 5:15 PM Magdalena Thurin 5:40 PM Maria Libera Ascierto Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment 6:05 PM Roundtable 6:50 PM Conclusions

3 December 4 th World-Wide Immunoscore Task Force: an Update Chairpersons: Paolo A. Ascierto, Francesco M. Marincola, Jerome Galon 9:30 AM Jerome Galon Immunoscore in the era of cancer immunotherapy 9:50 AM Paolo A. Ascierto Immunoscore and immunoprofiling in melanoma 10:10 AM Alessandro Lugli The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology 10:30 AM Break 10:45 AM Carlo Bifulco Next generation immunoprofiling 11:05 AM Giuseppe Masucci In search of personalized cancer immunotherapy 11:25 AM Magdalena Thurin 11:45 AM Franck Pages The immunoscore : toward an integrated immunomonitoring from the diagnosis to the follow up of cancer s patients 12:05 PM Roundtable 12:50 PM Conclusions 1:05 PM Lunch Economic Sustainability of melanoma treatments: Regulatory, Health Technology Assessment and Market Access issues Chairpersons: Paolo A. Ascierto, Pier Luigi Canonico 2:05 PM FDA representative 2:25 PM Jorge Camarero (EMA) Nivolumab, the regulatory experience in immunotherapy 2:45 PM Paolo Foggi (AIFA) 3:05 PM Deborah Morrison (NICE) 3:25 PM Break 3:40 PM Claudio Jommi Evidence to optimize access for melanoma drugs 4:00 PM Francesco de Lorenzo 4:20 PM Patients representatives Valerie Guild (AIM at Melanoma); Fondazione Melanoma 4:40 PM Roundtable Americo Cicchetti*, Paola Queirolo*, AIOM Representative 5:25 PM Conclusions * To be confirmed

4 FACULTY MELANOMA BRIDGE 2015 December 1-4, 2015 Sanjiv Agarwala St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania Maria Libera Ascierto Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland Paolo A. Ascierto Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute Fondazione G. Pascale of Naples, Italy Carlo Bifulco Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon Gerardo Botti National Cancer Institute Fondazione G. Pascale of Naples, Italy Jorge Camarero Oncology Area, Spanish Agency for Medicines and Medical Devices, AEMPS, Spain Oncology assessor at the European Medicines Agency, EMA Pier Luigi Canonico Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy Gennaro Ciliberto National Cancer Institute Fondazione G. Pascale of Naples, Italy Michael Davies Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Texas Francesco de Lorenzo Italian Federation of Volunteer-based Cancer Organizations, FAVO Sandra Demaria New York University School of Medicine and NYU Langone Medical Center Alexandria Center for Life Sciences, New York Reinhard Dummer University of Zurich Hospital, Department of Dermatology, Zurich Alexander Eggermont Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France Soldano Ferrone Massachusetts General Hospital, Boston, Massachusetts Paolo Foggi* Italian Medicines Agency, AIFA Bernard A. Fox Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon Yang Xin Fu Donnelley Biological Sciences Learning Center, University of

5 Chicago, Illinois Thomas F. Gajewski Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois Jerome Galon INSERM (National Institute of Health and Medical Research), Paris, France Claus Garbe Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany Valerie Guild AIM at Melanoma, Richmond, California Claudio Jommi Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy Samir Khleif Georgia Regents University Cancer Center, Augusta, Georgia John M. Kirkwood Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania Michael Krauthammer Yale University School of Medicine, New Haven, Connecticut Roger Lo Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California Alessandro Lugli Institute of Pathology, University of Bern, Switzerland Michele Maio Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Italy Francesco M. Marincola Sidra Medical and Research Center, Doha, Qatar Giuseppe Masucci Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden Deborah Morrison National Institute for Health and Care Excellence, NICE Nicola Mozzillo Department Melanoma and Soft Tissues, National Cancer Institute Fondazione G. Pascale of Naples, Italy Steven O'Day The Los Angeles Skin Cancer Institute, The Beverly Hills Cancer Institute in Beverly Hills, California Franck Pages Service d'immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France Giuseppe Palmieri Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy Michael Postow Memorial Sloan Kettering Cancer Center, New York Igor Puzanov Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee Licia Rivoltini National Cancer Institute of Milan, Italy Paola Queirolo National Institute for Cancer Research, Genova, Italy

6 Stefani Spranger Department of Patholog, University of Chicago, Illinois David Frank Stroncek Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland Ahmad Tarhini Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute, Pennsylvania Janis M. Taube Johns Hopkins University SOM, Baltimore, Maryland Alessandro Testori Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy Magdalena Thurin Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland Ena Wang Sidra Medical and Research Centre, Doha, Qatar Jennifer A. Wargo Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Cassian Yee Solid Tumor Cell Therapy and ACT Platform, UT MD Anderson Cancer Center, Texas Hassane Zarour University of Pittsburgh Cancer Institute Hillman Cancer Center, Pennsylvania